# Multiple Ascending Doses Study of CG400549

> **NCT01848470** · PHASE1 · COMPLETED · sponsor: **CrystalGenomics, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CG400549 640mg
- **DRUG:** CG400549 320 mg
- **DRUG:** CG400549 640 mg
- **DRUG:** CG400549 960 mg
- **DRUG:** Placebo 640mg
- **DRUG:** Placebo 320mg
- **DRUG:** placebo 960 mg
- **DRUG:** Placebo 640mg

## Key facts

- **NCT ID:** NCT01848470
- **Lead sponsor:** CrystalGenomics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01848470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01848470, "Multiple Ascending Doses Study of CG400549". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01848470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*